CLSI C31
Ionized Calcium Determinations: Precollection Variables, Specimen Choice, Collection, and Handling
CLSI C31 provides essential guidance for specimen collection and handling to ensure accurate ionized calcium determinations. Designed for laboratory professionals, this guideline explores factors that can alter ionized calcium concentrations, including both in vivo (nonpathologic) and in vitro changes. It offers best practices to minimize these effects, addressing preanalytical variables such as patient condition, specimen choice, collection, and handling. By following C31, laboratories can improve the clinical reliability of ionized calcium measurements.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceIonized Calcium Determinations: Precollection Variables, Specimen Choice, Collection, and Handling; Approved Guideline—Second Edition (CLSI document C31-A2) is a guideline for specimen collection for ionized calcium determinations. The primary audience for this publication is personnel responsible for ionized calcium determinations. This document discusses the reasons for in vivo (nonpathologic) and in vitro changes in ionized calcium concentrations, and it presents recommendations for avoiding or minimizing these effects.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This document is available in electronic format only.
This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid and because of its value to the laboratory community, it is being retained in CLSI’s library.
Ionized Calcium Determinations: Precollection Variables, Specimen Choice, Collection, and Handling; Approved Guideline—Second Edition (CLSI document C31-A2) is a guideline for specimen collection for ionized calcium determinations. The primary audience for this publication is personnel responsible for ionized calcium determinations. This document discusses the reasons for in vivo (nonpathologic) and in vitro changes in ionized calcium concentrations, and it presents recommendations for avoiding or minimizing these effects.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This document is available in electronic format only.
This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid and because of its value to the laboratory community, it is being retained in CLSI’s library.